Loading page
Skip to content
29th October 2026

Brixton Biosciences Announces Pivotal Clinical Data for Reneurx™ Nerve-Selective Therapy in Knee Osteoarthritis to be Presented at AAHKS 2026

26th October 2026

Brixton Biosciences Strengthens Executive Leadership Team to Support the Next Phase of Company Growth

18th August 2026

Brixton Biosciences Strengthens Board with Industry Veterans as Company Advances Towards Commercialization of Reneurx™ Nerve-Selective Therapy for Pain Associated with Knee Osteoarthritis

21st October 2025

Brixton Biosciences Announces Scientific Advisory Board Leadership

24th October 2024

Brixton Biosciences Receives $2M NIH HEAL Initiative Grant to Drive Drug-Free Pain Relief Innovations

14th May 2024

Brixton Biosciences Announces $35M in Series B Funding to Advance Novel Technology for the Treatment of Pain

25th October 2023

Brixton Biosciences’ Neural Ice™ Therapy granted Breakthrough Device designation by the FDA